Nymox Pharmaceutical Corporation (OTCPK: NYMX.F)
Health Care · Biotechnology · BS
$0.00
-99.00% today · -99.7% 1Y
Nymox Pharmaceutical Corporation (OTCPK: NYMX.F) operates in the Biotechnology industry within the Health Care sector. The company is valued at $21.01K and employs 3 people.
Over the last twelve months the share price has lost 99.7%, trading between 0.00 and 0.20.
Tweenvest scores Nymox Pharmaceutical Corporation across four factors: quality 8/100. Its strongest factor is quality.
NYMX.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $21.01K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 14.34
- 52-week high
- $0.20
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 105.04M
- Employees
- 3
- Next earnings
- —
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.
- ISIN
- BSP733981026
- Founded
- 1989
- Listed since
- Nov 26, 1997
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.